Single Cell Analysis and Immunogenetics

项目摘要 为这项赠款申请提出的项目旨在描述对治疗的反应和抗性， 造血干细胞移植（HCT）后的慢性移植物抗宿主病（cGVHD）。核心1将 支持这些项目的单细胞和免疫基因组学相关目标，重点应用最新的 实验和计算工具，这些研究。免疫组织化学的批量和单细胞转录组测序 和肺细胞群（目标1）将用于确定与治疗反应相关的相关途径， cGVHD，以鉴定在小鼠肺cGVHD模型中阐明的代谢特征的转录方面， 探讨闭塞性细支气管炎综合征的肺部发病机制和免疫反应 (BOS)HCT之后。T细胞对cGVHD治疗和对BOS的应答将进一步表征为： 使用靶向批量和单细胞测序进行TCR库分析以评估T细胞克隆性（目的2）。核心 1将分析供体和受体DNA的全外显子组测序数据，以确定多态性差异 在供体和受体之间，并使用组织表达数据库来确定这些变体中的哪一个是 在肺中表达。最近开发的复杂算法将被实现以使用该信息来 预测包含次要组织相容性抗原的个人HLA结合肽（Aim 3）。配对 α/β TCR链单细胞序列信息将用于重建表达个体TCR的细胞系。 富集的TCR（目的4），以便在功能上准确地确定哪个TCR与哪个抗原相互作用。这 分析将直接评估mHAg导向的T细胞应答是否有助于对治疗的临床应答。

Project Summary The projects proposed for this grant application seek to characterize response and resistance to treatments for chronic graft versus host disease (cGVHD) following hematopoietic stem cell transplantation (HCT). Core 1 will support the single cell- and immunogenomics-related goals of these projects by focusing on applying the latest experimental and computational tools to these studies. Bulk and single-cell transcriptome sequencing of immune and lung cell populations (Aim 1) will be used to identify relevant pathways related to response to treatment of cGVHD, to identify transcriptional aspects of the metabolic signature elucidated in mouse lung cGVHD models, and to characterize the lung pathogenesis and immune response related to Bronchiolitis Obliterans Syndrome (BOS) following HCT. Response of T cells to cGVHD treatments and to BOS will be further characterized by TCR repertoire analysis using targeted bulk and single-cell sequencing to assess T cell clonality (Aim 2). Core 1 will analyze whole exome sequencing data from donor and recipient DNA to identify polymorphic differences between donor and recipient, and use tissue expression databases to determine which of these variants are expressed in lung. Recently developed sophisticated algorithms will be implemented to use this information to predict personal HLA-binding peptides that comprise minor histocompatibility antigens (Aim 3). The paired alpha/beta TCR chain single-cell sequence information will be used to reconstruct cell lines expressing individual enriched TCRs (Aim 4) in order to functionally determine exactly which TCR interacts with which antigen. This analysis will directly assess if mHAg-directed T cell responses contribute to clinical responses to therapy.